New Drugs

Molecular targeted therapy of glioblastoma

Emilie Le Rhun[a,b], Matthias Preusser[c], Patrick Roth[a], David A. Reardon[d], Martin van den Bent[e], Patrick Wen[d], Guido Reifenberger[f], Michael Weller[a,*]

[a] Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland
[b] Neuro-oncology, Department of Neurosurgery, University Hospital, Lille, France
[c] Department of Medicine I, Division of Oncology, and Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
[d] Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
[e] Brain Tumor Center, Erasmus MC Cancer Institute, 3015 GD Rotterdam, Netherlands
[f] Institute of Neuropathology, Heinrich Heine University, Medical Faculty, Düsseldorf, and German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Germany

ARTICLE INFO

ABSTRACT

Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH)-wildtype tumors. Incidence increases with age, males are more often affected. Beyond rare instances of genetic predisposition and irradiation exposure, there are no known glioblastoma risk factors. Surgery as safely feasible followed by involved-field radiotherapy plus concomitant and maintenance temozolomide chemotherapy define the standard of care since 2005. Except for prolonged progression-free, but not overall survival afforded by the vascular endothelial growth factor antibody, bevacizumab, no pharmacological intervention has been demonstrated to alter the course of disease. Specifically, targeting cellular pathways frequently altered in glioblastoma, such as the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), the p53 and the retinoblastoma (RB) pathways, or epidermal growth factor receptor (EGFR) gene amplification or mutation, have failed to improve outcome, likely because of redundant compensatory mechanisms, insufficient target coverage related in part to the blood brain barrier, or poor tolerability and safety. Yet, uncommon glioblastoma subsets may exhibit specific vulnerabilities amenable to targeted interventions, including, but not limited to: high tumor mutational burden, BRAF mutation, neurotrophic tryrosine receptor kinase (NTRK) or fibroblast growth factor receptor (FGFR) gene fusions, and MET gene amplification or fusions. There is increasing interest in targeting not only the tumor cells, but also the microenvironment, including blood vessels, the monocyte/macrophage/microglia compartment, or T cells. Improved clinical trial designs using pharmacodynamic endpoints in enriched patient populations will be required to develop better treatments for glioblastoma.

Introduction

Glioblastoma is an intrinsic brain tumor that may occur at any age and is thought to originate by genetic alterations affecting neuroglial stem or progenitor cells [1]. Incidence increases steadily with age. Median age at diagnosis is in the range of 65 years, and males are approximately 1.7-fold more often affected than females. Young age and good performance status are therapy-independent positive prognostic factors.

The updated WHO classification from 2016 [2] separates two major types of glioblastoma based on mutations in the isocitrate dehydrogenase (IDH) 1 or 2 genes, with IDH-wildype glioblastomas

accounting for more than 90% of the cases. Histologically, glioblastomas are mitotically active tumors characterized by microvascular proliferation or necrosis or both as distinctive morphologic features of WHO grade IV. According to recent specifications of the consortium to inform molecular and practical approaches to CNS tumor taxonomy (cIMPACT) [3], molecular diagnostic detection of glioblastoma-associated genetic alterations, specifically epidermal growth factor receptor (EGFR) gene amplification, combined whole chromosome 7 gain and whole chromosome 10 loss ($+7/-10$), or telomerase reverse transcriptase (TERT) promoter mutation also allow for the diagnosis of IDH-wildtype glioblastoma despite the absence of WHO grade IV histological features. In contrast, astrocytic gliomas carrying an IDH mutation

also may exhibit typical histological features of glioblastoma, but typically are associated with a more favorable clinical course and hence may no longer be classified as glioblastoma in up-coming revisions of the WHO classification. This review thus is focussed on the common IDH-wildtype tumors. The 2016 WHO classification [2] has maintained giant cell glioblastoma and gliosarcoma as histological variants of IDH-wildtype glioblastoma, while, epithelioid glioblastoma was newly introduced as a provisional variant characterized by BRAF[V600E] mutation in up to 50% of cases [4], although more recent data did not identify distinct molecular profiles in these tumors [5]. While assigning a tumor to any of these variants has no clinical relevance in terms of tailoring standard treatment today [6], detection of BRAF[V600E] mutation in malignant gliomas including epithelioid glioblastomas may assume clinical relevance in terms of targeted therapy with mutant BRAF inhibitors (see below).

Besides histological variants, large-scale genetic and epigenetic profiling studies allowed for the distinction of several molecular subgroups of IDH-wildtype glioblastomas that are characterized by distinct DNA methylation patterns associated with characteristic mutational and expression profiles [7–9]. Up to seven molecular subgroups of IDH-wildtype glioblastoma have been identified by DNA methylation profiling, with the receptor tyrosine kinase (RTK) 1 and 2 subgroups as well as the mesenchymal subgroup being most common [9]. To date, distinction of these molecular subgroups is of limited relevance in terms of treatment, but this may change when future studies reveal subgroup-specific therapeutic vulnerabilities.

Current standard of care

Surgery as safely feasible followed by involved field radiotherapy in combination with concomitant and up to six maintenance cycles of temozolomide chemotherapy constitute the standard of care for the majority of patients with newly diagnosed glioblastoma [6,10]. Except for tumor-treating fields [11], no other therapeutic intervention has been shown to prolong overall survival in the newly diagnosed setting. All glioblastomas eventually progress, and standards of care at recurrence are less well defined. A small proportion of patients with localized recurrence are offered second surgery or re-irradiation, but neither of these interventions has been shown to prolong survival. Another course of alkylating chemotherapy, mostly the nitrosourea compound, lomustine, is the most broadly used intervention at recurrence and also constitutes the control arm in recent randomized trials in recurrent glioblastoma [12]. Yet, neither lomustine nor any other systemic treatment nor tumor-treating fields [13] have been shown to be superior to placebo or best supportive care in a randomized trial.

Targeted therapy for glioblastoma: Focus on *MGMT* promoter methylation

Benefit from alkylating agent chemotherapy in glioblastoma is largely limited to patients whose tumors show aberrant CpG methylation of the promoter region of the O^6-methylguanine DNA methyltransferase (*MGMT*) gene. *MGMT* promoter methylation has been established as a predictive biomarker for benefit from temozolomide, although firmly only in the newly diagnosed setting [14,15]. The AVAREG trial assessing fotemustine and bevacizumab appeared to confirm this predictive value also for a nitrosourea compound in the recurrent setting [16]. However, the REGOMA trial (see below), which also provided data on, albeit locally determined, MGMT status did not confirm a predictive value of MGMT promoter methylation for benefit from lomustine compared to regorafenib [17]. Since several large controlled trials with central MGMT testing have confirmed a strong prognostic role of MGMT promoter methylation in recurrent glioblastoma patients treated with temozolomide [18] or lomustine [12,19], the potential predictive role of the MGMT status at recurrence needs to be further studied.

Drug repurposing

An emerging area of interest in cancer therapy, notably glioblastoma, is the repurposing of drugs that are already approved for other indications, based on assumptions of biochemical or metabolic features that might confer glioma cell sensitivity to such drugs. Importantly, retrospective analyses of survival associations of all these drugs need to be interpreted with caution and should be considered hypothesis-generating only. This is because it is difficult to control for comorbidities that led to the administration of these drugs, dosing was never standardized and not optimized for demonstrating anti-tumor activity, and data collection was typically limited to landmark analyses, but not cumulative dosing.

Anti-epileptic drugs

Despite decades of research, no conclusive evidence to support a survival-promoting activity of anti-epileptic drugs in brain tumor patients has been obtained. Mainly based on histone deacetylase inhibitory activity seen at high concentrations *in vitro* and putative differentiation-inducing activity, valproic acid has attracted particular interest. The observation of longer survival of patients treated with valproic acid in the EORTC 26981 trial [20] was not confirmed in an analysis of subsequent larger clinical trial populations [21], but the combination of valproic acid with temozolomide chemoradiotherapy continues to be explored [22]. Levetiracetam has been proposed to decrease the level of MGMT in glioblastoma [23], but no association with favorable outcome was seen in a large secondary analysis of clinical trial data [21]. Finally, after significant interest in the role of glutamatergic signaling affecting neurotransmission in the biology of glioblastoma, the initial excitement on the AMPA receptor antagonist, talampanel, subsided when it became clear that single arm phase II studies often generate signals interpreted as promising, but are not predictive of success in randomized phase III settings [24] (see below).

Metformin

This anti-diabetic drug has been advanced as an adjunct to glioblastoma treatment because of presumed modulatory effects on metabolism, notably lowering glucose availability, suppression of insulin-like growth-factor signaling, and specifically inhibition of AMP-activated protein kinase. Yet, current evidence from pooled retrospective analyses of clinical trial data does not support the view that metformin warrants further study in glioblastoma [25].

Glioblastoma-intrinsic targets

The majority of clinical trial approaches focusing on glioblastoma-intrinsic targets address oncogenic signaling via tyrosine receptor kinases, cell cycle control and susceptibility to apoptosis induction (Figs. 1 and 2).

Tyrosine kinase receptor pathways

Epidermal growth factor receptor (EGFR)

EGFR is one of most prominent oncogenes in IDH-wildtype glioblastoma. It is overexpressed in approximately 60% of tumors, and more than 40% exhibit *EGFR* gene amplification. A particular deletion mutation referred to as EGFRvIII or delta-EGFR is found in 25% of tumors and is of particular interest since it is constitutively active and a potential neoantigen (Table 1). Numerous studies have failed to demonstrate single agent activity of EGFR tyrosine kinase inhibitors in unselected patient populations and small biological endpoint studies have raised concerns that these drugs may not be able to suppress pathway activity even if they reach the tumor tissue [26,27]. Other approaches have used EGFR or EGFRvIII expression rather than EGFR

Tumor cell

Fig. 1. Candidate molecular pathways amenable to targeted interventions in glioblastoma.

pathway activity as a target: these include the vaccine, rindopepimut, which produced a survival signal when combined with bevacizumab in EGFRvIII-positive recurrent glioblastoma (NCT01498328), but failed in phase III (ACT IV) in newly diagnosed disease [28]. Similarly, the antibody drug conjugate, depatuxizumab mafodotin, consisting of the EGFR antibody ABT-806 linked to monomethyl auristatin F, appeared to be active in combination with temozolomide in recurrent *EGFR*-amplified glioblastoma [29], but showed no activity in newly diagnosed glioblastoma when combined with standard temozolomide chemoradiotherapy (NCT02573324). The ACT IV trial results showed a striking loss of EGFRvIII expression at recurrence in both groups of the trial, suggesting that EGFRvIII expression is unstable. These observations of unstable target expression also cast doubt on the likelihood of success of chimeric antigen receptor (CAR) T cells or bispecific T-cell engaging antibodies targeting EGFRvIII [30,31]. In contrast, EGFR amplification appears to be maintained throughout the course of disease [32,33].

PI3K/AKT/mTOR pathway

The PI3K/mTOR pathway is one of the almost inevitably altered molecular pathways in IDH-wildtype glioblastoma, as a consequence of loss of tumor suppressor phosphatase and tensin homolog on chromosome ten (PTEN) function, activating mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (*PIK3CA)*, the gene encoding the catalytic subunit p110 alpha (p110α), and in phosphoinositide-3-kinase regulatory subunit 1 (*PIK3R1)*, encoding the p85α regulatory subunit. Yet, like in other types of cancer, it has turned out to be challenging to translate this extensive knowledge on pathway alteration into clinical benefit, although there is a long tradition of targeting the PI3K pathway in glioblastoma.

As early as 2005, the lack of activity of the mTOR inhibitor, temsirolimus (CCL-779), was demonstrated at least when used as a single agent in recurrent glioblastoma [34]. It was also observed at this time that the toxicity profile was unfavorable in this patient population. More recently, in a similar setting but enrolling patients predicted to be enriched for active PI3K signaling, the pan-PI3K inhibitor, buparlisib was found to be essentially inactive. This trial included a phase 0-like biological endpoint cohort. A subset of patients exhibited reduced levels of phosphorylated AKT^{S473} in the tumor tissue as a direct read-out of PI3K inhibition, but suppression of down-stream $pS6^{S235/236}$ was less pronounced, demonstrating insufficient overall pathway inhibition by tolerable doses of buparlisib [35].

PI3K/mTOR pathway inhibition has also been explored in the newly diagnosed setting, either in combination with radiotherapy and temozolomide [36] or instead of temozolomide in patients with MGMT

promoter-unmethylated glioblastoma [37]. Both trials concluded absence of an efficacy signal and both confirmed the relatively poor tolerability of mTOR inhibitors in this setting, at least compared with temozolomide.

In summary, it seems that the PI3K/AKT/mTOR pathway is overall too promiscuous, resulting in non-favorable tolerability and safety profiles upon pharmacological inhibition. Moreover, well designed clinical trials have indicated that currently available agents may be insufficient to inhibit the target adequately at doses that are tolerated by patients. One may speculate that even those tumors that are in principle sensitive to target inhibition will rapidly develop escape pathways, circumventing the block of the PI3K pathway. Future efforts will have to employ more potent agents or will have to rely on combinatorial strategies, the development of which, however, probably requires a deeper understanding of how this pathway interacts with other pathways that are likely to be altered in glioblastoma.

MET

The *MET* gene encodes the receptor for hepatocyte growth factor, also known as scatter factor, and has been attributed a major role in the migration and invasiveness of glioma cells, notably in response to irradiation, inhibition of angiogenesis, and hypoxia [38]. It is commonly expressed in glioblastoma, often at high levels, but not a major mutational target (Table 1). Proof of concept for a role of MET amplification was obtained in a single patient with recurrent glioblastoma treated with crizotinib [39], but not in a second published case [40]. However, neutralizing the ligand appeared to have no impact on disease progression [41]. Blocking the receptor using the single arm antibody, onartuzumab [42] or cabozantinib, a tyrosine kinase inhibitor of MET, VEGFR2 and AXL, in patients without or with pre-exposure to antiangiogenic agents [43,44] resulted in a modest efficacy signal in recurrent disease. MET fusion genes have been detected in a minor subset of pediatric glioblastoma and have been linked to response to crizotinib in one patient [45].

Fibroblast growth factor receptor (FGFR)

FGFR are commonly expressed in glioblastomas, but relevance as a potential target for intervention is probably limited to patients with rare tumors exhibiting FGFR-TACC fusions [46]. Despite several ongoing efforts in this area, there is little data available in the public domain. One stable disease and one minor response were reported in two patients with FGFR3-TACC3-positive recurrent glioblastoma patients treated with the oral pan-FGFR kinase inhibitor, erdafitinib [47].

Fig. 2. Selected current strategies of targeted therapy for glioblastoma. A, EGFR; B, PI3K/AKT/mTOR; C, MET, D, FGFR; E, BRAF; F, NTRK; G, VEGF; H, Integrins; I, TGF-β.

Table 1
Candidate target molecules for molecular therapy of IDH wildtype glioblastoma.

Target	Biological function	Significance in glioblastoma	Selected references
Glioblastoma-intrinsic targets			
Epidermal growth factor receptor (EGFR)	Proliferation, invasion, resistance to apoptosis induction	Amplification in 40–50%, including EGFRvIII mutation in half of these, 10–20% overexpression without amplification	Brennan et al. 2013 [8], Felsberg et al. 2017 [33]
PI3K/AKT/mTOR	Metabolism, proliferation, migration	Almost uniformly activated pathway due to loss of *PTEN* function or activating mutations in *PIK3CA* or *PIK3R1*	Brennan et al. 2013 [8]
MET	Migration, invasion, wound healing	Overexpression, rarely amplification (5%)	Brennan et al. 2013 [8], Kwak et al. 2015 [79]
FGFR	Proliferation	FGFR transforming acidic coiled-coil (TACC) gene fusions (3%) and very rarely activating mutations	Singh et al. 2012 [46], Di Stefano et al. 2015 [47]
BRAF	Proliferation	BRAFV600E mutations in up to 50% of epithelioid glioblastomas, otherwise rare	Korshunov et al. 2018 [5]
NTRK	Proliferation	NTRK gene fusions detected in 1–2%	Ferguson et al. 2018 [52]
CDK4/6 or CDKN2A/B or RB	Cell cycle progression	Pathway often disrupted, because of CDK4/6 amplification (15%), CDKN2A/B loss (50%) or RB mutation (10%)	Brennan et al. 2013 [8]
P53	Cell cycle progression and apoptosis induction	Mutation or deletion (35%) or neutralization by MDM2/4 amplification (20%)	Brennan et al. 2013 [8]
TERT	Proliferation, cellular longevity	Enhanced expression resulting from promoter mutation (90%)	Brennan et al. 2013 [8]
Microenvironmental targets			
Vascular endothelial growth factor (VEGF)	Blood vessel formation	Angiogenesis triggered by hypoxia, potentially survival factor for subsets of glioblastomas	Plate et al. 1994 [80], Szabo et al. 2016 [65]
Integrins	Adhesion, migration, adhesion, activation of TGF-β pathway	αv integrins are expressed in blood vessels and tumor cells	Roth et al. 2013 [69]
TGF-β	Pleiotropic cytokine involved in most biological processes	Immunosuppression, migration, invasion, angiogenesis	Frei et al. 2015 [81]
PD-L1	Immune checkpoint, limiting T cell activation	Expression levels in glioblastoma including tumor microenvironment remain controversial	Berghoff et al. 2015 [82], Nduom et al. 2016 [83]

BRAF mutation

BRAF, a member of the Raf family of kinases, feeds into the MAP kinase/ERK signaling pathway that promotes proliferation. Activating BRAF mutations, in particular the BRAF^{V600E} missense mutation, are found in several tumor types and have been confirmed to be druggable molecular lesions, notably in metastatic melanoma [48]. Early studies and individual case reports indicated that glial tumors exhibiting BRAF mutations may also respond to pharmacological BRAF inhibition, although their efficacy seems modest at best in BRAFV600E-mutant glioblastoma [49–51].

Neurotrophic tyrosine receptor kinases (NTRK)

NTRK are encoded by three different genes, *NTRK1*, *NTRK2* and *NTRK3*. Genomic rearrangements in *NTRK* genes resulting in gene fusions may trigger activation of oncogenic TRK signaling. The prevalence of *NTRK* gene fusions in glioblastoma appears to be low [52], and larger studies are required to determine whether agents like larotrectinib or entrectinib are also active in NTRK fusion-positive glioblastoma [53].

Cell cycle control and apoptosis regulating pathways

The retinoblastoma (pRB) pathway

The pRB cell cycle control pathway is altered in the majority of IDH-wildtype glioblastomas due to homozygous *CDKN2A/B* deletion, *CDK4* or *CDK6* amplification, or *RB1* gene alterations (Table 1). This pathway is also required for the growth of normal cells which may largely explain why its therapeutic targeting has remained challenging, not only in glioblastoma. The only completed phase II trial targeting this pathway in glioblastoma using palbociclib was disappointing [54], but patients enrolled in this trial represented a negative selection, as indicated by the short overall survival (Table 2).

TG02 is a multi-CDK inhibitor mainly targeting CDK9, but not CDK4/6, and acts independently of the cell cycle control pathway involving CDK4/6 to suppress the transcription of multiple short-lived survival genes. TG02 is currently being explored in clinical trials in recurrent and in newly diagnosed glioblastoma (NCT02942264, NCT03224104).

The p53 pathway

The *TP53* tumor suppressor gene is among the best and longest studied genes in glioblastoma. Since the key function of its gene product, p53, is to arrest cells in G0/1 or to trigger apoptosis in response to genotoxic stress, restoring p53 function by various approaches has been extensively studied. Yet, drugs aimed at facilitating refolding of mutant proteins into wildtype conformation have not been successful, but efforts focusing on neutralizing MDM2 and MDM4 for patients with glioblastomas that are deficient in p53 function as a consequence of MDM2 or MDM4 gene amplification are in progress ([55] and NCT03107780).

TERT promoter mutation

TERT promoter mutations are the most common molecular alteration in IDH-wildtype glioblastoma [8,56]. They affect two mutation hotspots that create new Ets transcripton factor-binding sites and increase TERT transcription and thereby TERT activity supporting immortalization of tumor cells [57]. Nevertheless, TERT promoter mutation has not become a major pharmacological target for cancer therapy yet. Eribulin, known as an inhibitor of tubulin polymerization, has been proposed to exert TERT inhibitory activity in glioblastoma models, justifying its clinical exploration [58].

Proteasome

The proteasome is a complex cellular machinery with several enzymatic activities involved in the degradation and recycling of cellular protein. Altered proteasome activity has emerged as a potential vulnerability of cancer cells and resulted in the development of drugs like bortezomib that have also been tested in recurrent glioblastoma [59,60]. The brain-penetrant pan-proteasome inhibitor, marizomib, is currently undergoing phase III evaluation in newly diagnosed glioblastoma (NCT03345095).

Microenvironmental targets - angiogenesis

Vascular endothelial growth factor (VEGF)

The detection of VEGF as a major mediator of angiogenesis in

Table 2
Selected phase II and III trials of targeted therapy in glioblastoma.

Reference && selected trials	Intervention	Patient population (n)	Enrichment	Design	Primary endpoint	Response	PFS	OS	Conclusions
Glioblastoma-intrinsic targets									
EGFR									
Van den Bent et al. 2009 [84]	Erlotinib	Recurrent, erlotinib (54) versus BCNU or TMZ (56)	None	Randomized phase II. open label	PFS-6	Erlotinib PR: 3,7% BCNU/TMZ PR: 9.6%	PFS-6 (%) Erlotinib 11.4 BCNU/TMZ 24 median PFS (months) erlotinib 1.8 BCNU/TMZ 2.4	Median OS (months) erlotinib 7.7 BCNU/TMZ 7.3	EGFR TKI do not provide benefit in unselected patients
Weller et al. 2017 [28]	Rindopepimut	Newly diagnosed, rindopepimut (371) versus control (374), plus TMZ/RT → TMZ	EGFRvIII expression	Randomized phase III, placebo-controlled	OS		Median PFS (months) rindopepimut 7.1 placebo 5.6	Median OS (months) rindopepimut 20.1 placebo 20.0	Rindopepimut is inactive in newly diagnosed disease
van den Bent et al. 2018 [29]	Depatuxizumab / ABT-414	Recurrent, ABT-414 plus TMZ (88) versus ABT-414 (86) versus TMZ or CCNU (86)	EGFR amplification	Randomized phase II, open label	OS	ABT-414 plus TMZ 5 PR ABT-414 2 PR TMZ/CCNU 1 PR	Median PFS (months) ABT-414 plus TMZ 3 ABT-414 1.9 TMZ/CCNU 2.0	Median OS (months) ABT-414 plus TMZ 9.6 ABT-414 7.9 TMZ/CCNU 8.2	ABT-414 may be active in combination with TMZ
PI3K/AKT/mTOR									
Chang et al. 2005 [34]	Temsirolimus	Recurrent (43)	None	Single arm phase II	PFS-6	2 PR	PFS-6 2%	ND	Temsirolimus is inactive as single agent
Ma et al. 2015 [36]	Everolimus	Newly diagnosed (1 0 4), plus TMZ/RT → TMZ	None	Single arm phase II	OS-12		median PFS 6.4 months	OS-12: 64% median OS: 15.8 months	Everolimus is not active in combination with TMZ/RT → TMZ
Wick et al. 2016 [37]	Temsirolimus	Newly diagnosed, temsirolimus plus RT (56) or TMZ/RT → TMZ (55)	None, MGMT promoter unmethylated	Randomized phase II, open label	OS-12		Median PFS (months) temsirolimus 5.4 TMZ 6.0	OS-12 Temsirolimus 70% TMZ 72% Median OS (months) Temsirolimus 14.8 TMZ 16.0	mTOR^{Ser2448} phosphorylation may be used for enrichment in further studies of mTOR inhibition
Wen et al. 2019 [35]	Buparlisib	Recurrent (50)	PI3K pathway activated	Single arm phase II	PFS-6	None	PFS-6 8%	9.8 months	Buparlisib is inactive as single agent
MET									
Wen et al. 2011 [41]	Rilotumumab	Recurrent (60), rilotumumab at 10 or 20 mg/kg	None	Single arm phase II	ORR	None	PFS (months) 10 mg/kg: 1.0 20 mg/kg: 1.0	OS (months) 10 mg/kg: 6.5 20 mg/kg: 5.4	Rilotumumab is inactive
Cloughesy et al. 2017 [42]	Onartuzumab	Recurrent, onartuzumab plus bevacizumab (64) or bevacizumab (65)	None	Randomized phase II, open label	PFS-6	onartuzumab plus bevacizumab 1 CR, 11 PR bevacizumab 3 CR, 11 PR	PFS-6 (months) onartuzumab plus bevacizumab 3.9 bevacizumab 2.9	OS (months) onartuzumab plus bevacizumab 8.8 bevacizumab 12.6	High tumor hepatocyte growth factor and lack of MGMT promoter methylation may predict benefit from MET inhibition
BRAF									
Kaley et al. 2018 [49]	Vemurafenib	BRAF-mutant glioma (24), including 6 glioblastomas	BRAF mutation	Single arm phase II	ORR	None, 3 SD in 6 patients			BRAF inhibition in glal brain tumors deserves further study
CDK4/6 or CDKN2A/ B or RB									
Taylor et al. 2018 [54]	Palbociclib	Recurrent (22)			PFS-6		Median PFS 5 weeks		

(continued on next page)

6

Table 2 (*continued*)

Reference && selected trials	Intervention	Patient population (n)	Enrichment	Design	Primary endpoint	Response	PFS	OS	Conclusions
			RB1-positive by immune-histochemistry	Single arm phase II				Median OS 15 weeks	Palbociclib is inactive as single agent
Proteasome									
Friday et al. 2012 [60]	Bortezomib plus vorinostat	Recurrent (34)	None	Single arm phase II	PFS-6	1 PR	PFS-6: 0%	Median OS 3.2 months	No indication to further study this combination
Kong et al. 2018 [59]	Bortezomib	Recurrent (24)	None	Single arm phase II	OS		Median PFS 6.2 months	Median OS 19.1 months	Bortezomib warrants further study
Multi-kinase inhibition									
Lee et al. 2016 [85]	Vandetanib[1]	Newly diagnosed, TMZ/RT → TMZ (36) or TMZ/RT → TMZ plus vandetanib (70)	None	Randomized phase II, open label	OS		PFS (months) TMZ/RT → TMZ 6.2 TMZ/RT → TMZ plus vandetanib 7.7	OS (months) TMZ/RT → TMZ 15.9 TMZ/RT → TMZ plus vandetanib 16.6	Vandetanib is inactive
Wen et al. 2018 [44]	Cabozantinib[2]	Recurrent, without prior anti-angiogenic therapy (34 at 140 mg/d, 118 at 100 mg/d)	None	Single arm phase II	ORR	6 PR and 17 PR	PFS-6: 22.3% and 27.8%	Median OS 7.7 and 10.4 months	Cabozantinib is inactive as single agent
Cloughesy et al. 2018 [43]	Cabozantinib	Recurrent, with prior anti-angiogenic therapy (70)	None	Single arm phase II	ORR	3 PR	PFS-6: 8.5%	Median OS 4.6 months	Cabozantinib is inactive as single agent
Lombardi et al. 2018 [17]	Regorafenib[3]	Recurrent, regorafenib (59) versus lomustine (60)	None	Randomized phase II, open label	OS	Regorafenib 1 CR, 2 PR Lomustine 1 CR, 1 PR	PFS-6 Regorafenib 16.9% Lomustine 8.3%	OS (months) Regorafenib 7.4 Lomustine 5.6	Regorafenib warrants further study in glioblastoma
Microenvironmental targets									
VEGF									
Kreisl et al. 2009 [61]	Bevacizumab	Recurrent (48)	None	Single arm phase II	PFS-6	1 CR, 16 PR	PFS-6 29%	OS 7.2 months	Bevacizumab is active
Friedman et al. 2009 [62]	Bevacizumab	Recurrent, bevacizumab (85) or bevacizumab plus irinotecan (82)	None	Randomized phase II, open label	PFS-6 and ORR	Bevacizumab 1 CR, 23 PR bevacizumab plus irinotecan 2 CR, 29 PR	PFS-6 bevacizumab 43% bevacizumab plus irinotecan 50%	OS (months) bevacizumab 9.2 bevacizumab plus irinotecan 8.7	Bevacizumab is active
Chinot et al. 2014 [67]	Bevacizumab	Newly diagnosed, TMZ/RT → TMZ (463) or TMZ/RT → TMZ plus bevacizumab (458)	None	Randomized phase III, placebo-controlled	Investigator-assessed PFS and OS		PFS (months) control 6.2 bevacizumab 10.6	OS (months) control 16.7 bevacizumab 16.8	Bevacizumab does not prolong OS
Gilbert et al. 2014 [66]	Bevacizumab	Newly diagnosed, TMZ/RT → TMZ (317) or TMZ/RT → TMZ plus bevacizumab (320)	None	Randomized phase III, placebo-controlled	OS and PFS		PFS (months) control 7.3 bevacizumab. 10.7	OS control 16.1 bevacizumab 15.7 months	Bevacizumab does not prolong OS
Herrlinger et al. 2016 [86]	Bevacizumab	Newly diagnosed, TMZ/RT → TMZ (54) or RT plus bevacizumab plus irinotecan (116)	None, MGMT promoter unmethylated	Randomized phase II, open label	PFS		PFS-6: TMZ/RT → TMZ 43% RT plus bevacizumab plus irinotecan 79%	OS (months) TMZ/RT → TMZ 17.5 RT plus bevacizumab plus irinotecan 16.6	Trial results inconclusive
Taal et al. 2014 [19]	Bevacizumab	Recurrent, lomustine or bevacizumab or	None		OS-9	ORR lomustine 5% bevacizumab 38%	PFS-6 lomustine 13%	OS-9 lomustine 38%	

7

Table 2 (*continued*)

Reference && selected trials	Intervention	Patient population (n)	Enrichment	Design	Primary endpoint	Response	PFS	OS	Conclusions
		bevacizumab plus lomustine		Randomized phase II, open label		bevacizumab plus lomustine 34%	bevacizumab 16% bevacizumab plus lomustine 41%	bevacizumab 43% bevacizumab plus lomustine 87%	Bevacizumab plus lomustine may be superior to monotherapy
Wick et al. 2017 [12]	Bevacizumab	Recurrent, bevacizumab plus lomustine (288) or lomustine (149)	None	Randomized phase III, open-label	OS	Bevacizumab plus lomustine 5 CR, 103 PR lomustine 1 CR, 18 PR	PFS (months) bevacizumab plus lomustine 4.2 lomustine 1.5	OS (months) bevacizumab plus lomustine 9.1 lomustine 8.6	Bevacizumab does not prolong OS
Wirsching et al. 2018 [64]	Bevacizumab	Newly diagnosed, hypofractionated RT plus bevacizumab (n = 50) or RT alone (n = 25)	Elderly patients (65 years or more), MGMT promoter unmethylated (after amendment)	Randomized phase II	OS	Bevacizumab plus RT 6 CR, 17 PR RT 4 CR, 3 PR	PFS-6 Bevacizumab plus RT 78% RT 28% PFS Bevacizumab plus RT 7.6 RT 4.8	OS (months) Bevacizumab plus RT 12.1 RT 12.2	Old age and absence of MGMT promoter methylation fail to predict improved OS with bevacizumab
De Groot et al. 2011 [87]	Aflibercept (VEGF trap)	Recurrent (42)	None	Single arm phase II	PFS-6	7 PR	PFS-6 8%	OS 9.1 months	Aflibercept is inactive
Batchelor et al. 2010 [88]	Cediranib	Recurrent (31)	None	Single arm phase II	PFS-6	8 PR	PFS 3.9 months	OS 7.6 months	Cediranib warrants further study
Batchelor et al. 2013 [68]	Cediranib	Recurrent, cediranib (131) or cediranib plus lomustine (129) or lomustine (65)	None	Randomized phase III, partially blinded	PFS	Cediranib 1 CR, 17 PR cediranib plus lomustine 2 CR, 19 PR lomustine 5 PR	PFS (months) cediranib 3.1 cediranib plus lomustine 4.2 lomustine 2.7	OS (months) cediranib 8.0 cediranib plus lomustine 9.4 lomustine 9.8	Cediranib is not superior to lomustine and does not prolong survival in combination
Integrins									
Reardon et al. 2008 [89]	Cilengitide	Recurrent, cilengitide high (40) or low (41) dose	None	Randomized phase II, open label	PFS-6	high 5 responses low 2 responses	PFS-6 high 15% low 10%	OS (months) high 9.9 low 6.5	Cilengitide is moderately active
Stupp et al. 2010 [70]	Cilengitide	Newly diagnosed, TMZ/RT → TMZ plus cilengitide (52)	None	Single arm phase II	PFS		PFS 8 months	OS 16.1 months	Cilengitide warrants further study
Nabors et al. 2012 [90]	Cilengitide	Newly diagnosed, TMZ/RT → TMZ plus cilengitide high (48) or low (46) dose	None	Randomized phase II, open label	OS		PFS (months) high 9.3 low 9.5	OS (months) high 20.8 low 17.4	Cilengitide warrants further study
Stupp et al. 2014 [71]	Cilengitide	Newly diagnosed, TMZ/RT → TMZ without (273) or with cilengitide (272)	None, MGMT promoter methylated	Randomized phase III, open label	OS		PFS (months) control 7.9 cilengitide 10.6	OS 26.3 in both arms	Cilengitide is inactive
Nabors et al. 2015 [91]	Cilengitide	Newly diagnosed, TMZ/RT → TMZ without (89) or with cilengitide high (88) or low (88) dose	None, MGMT promoter unmethylated	Randomized phase II, open label	OS		PFS (months) Control 4.1 low 5.6 high 5.9	OS (months) control 13.4 low 16.3 high 14.5	Inconclusive study results
Angiopoietins									
Reardon et al. 2018 [92] 2018	Trebananib	Recurrent, trebananib (11) or trebananib plus bevacizumab (37)	None	Single arm phase II	PFS-6	Trebananib none trebananib plus bevacizumab 10 PR	PFS-6 Rebananib 0% trebananib plus bevacizumab 24%	OS (months) Trebananib 11.4 trebananib plus bevacizumab 9.5	Trebananib is inactive
PKC									
Wick et al. 2010 [93]	Enzastaurin	Recurrent, enzastaurin (266) or lomustine (92)	None		PFS	enzastaurin 5 responses			Enzastaurin is inactive

Table 2 (*continued*)

Reference && selected trials	Intervention	Patient population (n)	Enrichment	Design	Primary endpoint	Response	PFS	OS	Conclusions
Wick et al. 2013 [94]	Enzastaurin	Newly diagnosed (60)	None, MGMT promoter unmethylated	Single arm phase II	PFS-6	lomustine 4 responses	PFS (months) enzastaurin 1.5 lomustine 1.6 PFS-6 54%	OS (months) enzastaurin 6.6 lomustine 7.1 OS 15 months	Enzastaurin is inactive
TGF-β									
Bogdahn et al. 2011 [72]	Trabedersen (TGF-β2 antisense oligonucleotide)	Recurrent, Trabedersen high (34) or low (28) dose or TMZ/PCV (33)	None	Randomized phase II, open label	6 months tumor control rate	Trabedersen high 1 PR, low none, TMZ/PCV none	Tumor control rate Trabedersen high 12%, low 14%, TMZ/PCV 15%	OS (months) Trabedersen high 10.9, low 7.3, TMZ/PCV 10	Trabedersen should be further evaluated (at the time)
Brandes et al. 2016 [73]	Galunisertib	Recurrent, galunisertib plus lomustine (79), galunisertib (39), lomustine (40)	None	Randomized phase II, partially blinded	OS	galunisertib plus lomustine 1 CR galunisertib 2 PR lomustine none	PFS (months) galunisertib plus lomustine 1.8 galunisertib 1.8 lomustine 1.9	OS (months) galunisertib plus lomustine 6.7 galunisertib 8.0 lomustine 7.5	Galunisertib is inactive
Glutamate receptors									
Iwamoto et al. 2010 [95]	Talampanel	Recurrent (22)	None	Single arm phase II	PFS-6	1 PR	PFS-6 5%	OS 3 months	Talampanel is inactive in this setting
Grossmann et al. 2009 [24]	Talampanel	Newly diagnosed, TMZ/RT → TMZ plus talampanel (72)	None	Single arm phase II	OS			OS 18.3 months	Tamlampanel may be further evaluated
CD95 ligand									
Wick et al. 2014 [96]	APG-101	Recurrent, RT (26) or RT plus APG-101 (58)	None	Randomized phase II, open label	PFS-6		PFS 6 RT 4% RT plus APG-101 21%	OS 11.5 months in both arms	APG-101 warrants further study
PD-1									
Reardon et al. 2017 [75]	Nivolumab	Recurrent, nivolumab (184) or bevacizumab (185)	None	Randomized phase III, open label	OS	Nivolumab 12 responses Bevacizumab 36 responses	Median PFS (months) Nivolumab 1.5 Bevacizumab 3.5	OS (months) Nivolumab 9.8 Bevacizumab 10.0	Nivolumab may be active in patients with MGMT promoter-methylated tumors who are not on steroids

Abbreviations: ND no data, OS overall survival, PCV procarbacin lomustine vincristine, PFS progression-free survival, TMZ temozolomide.
1 Inhibits VEGFR2, EGFR, RET.
2 Inhibits VEGFR2, MET, AXL.
3 Inhibits VEGFR1-3, TIE2, KIT, RET, RAF1, BRAF, PDGFR, FGFR, CSF1R.

Table 3

Outlook on improved drug development in glioblastoma.

Limitations and challenges	Solutions
Molecular testing not standardized and not reimbursed	Centralization, implementation into guidelines and proactive dialog with health care providers
Patient selection	Avoid selecting last-line patients and focus on biomarker-enriched patient populations
Insufficient drug development strategies	Early proof-of-concept (window of opportunity studies) with pharmacodynamic and biological endpoints and inclusion of glioblastoma patients in basket trials for tumors with defined molecular alterations
Administrational barriers impeding international cooperations	Parallel trials and efforts to increase public awareness in order to change legislation to facilitate international cooperation

glioblastoma, at a time when conventional cancer treatments like radiotherapy and chemotherapy appeared to have reached their limits, triggered substantial efforts to establish anti-angiogenesis as a treatment paradigm in glioblastoma (Table 2). Based on high radiological response rates and encouraging survival outcomes in uncontrolled trials [61,62], bevacizumab achieved approval for recurrent glioblastoma in many parts of the world, but its effects on tumor biology and growth dynamics beyond what can be detected by neuroimaging remained controversial. It has remained challenging to identify subgroups of glioblastoma patients that experience prolonged survival when treated with bevacizumab [63,64], although there are glioblastoma models where VEGF may even be a survival factor [65]. Phase III trials in newly diagnosed and recurrent disease demonstrated prolonged PFS but consistently no OS benefit, although approximately 30% cross-over to bevacizumab was observed in these trials [12,66,67]. Other VEGF inhibitors such as cediranib also failed in randomized clinical trials [68].

Integrins

Integrins are cell surface molecules that integrate signals from cell to cell and extracellular matrix to cell and are involved in essential cellular processes such as adhesion, migration, invasion and angiogenesis. Specific subtypes of integrins are present in glioblastomas and their vasculature [69]. The results of a series of largely uncontrolled clinical trials were interpreted to justify a phase III trial on cilengitide in patients enriched for *MGMT* promoter methylated glioblastomas [70,71]. Altogether, these trials did not provide any robust safety or efficacy signal using cilengitide as a lead compound for integrin inhibition, but efforts to employ tumor specific integrin expression as a target continue.

Transforming growth factor (TGF)-β

TGF-$\beta_{1/2}$ as the major representatives of a family of related proteins have been considered for decades as key molecules responsible for glioblastoma-mediated immunosuppression. However, this protein family is promiscuous in that it is involved in almost all physiological and pathological processes. Despite promising data obtained with various modes of TGF-β inhibition in different animal models, clinical translation of TGF-β targeting using TGF-β2-specific antisense oligonucleotides [72] or tyrosine kinase inhibitors targeting TGF-β receptor II (ALK5) such as galunisertib [73] has remained unsuccessful. The introduction of TGF-β receptor inhibitors into the clinic has also remained challenging because of dose-limiting toxicity, e.g, to the cardiac and intestinal system, potentially preventing adequate target coverage in the tumor.

Programmed cell death protein (PD)-1

The development of neutralizing antibodies to immune checkpoint molecules has dominated the field of cancer immunotherapy. Notably antibodies preventing the engagement of PD-1 on T cells by is major ligand, PD-L1, expressed on tumor cells, or on host cells have attracted marked interest. Yet, despite major advances in the treatment of various solid tumors with immune checkpoint inhibition, e.g., melanoma or non-small cell lung cancer, immune checkpoint inhibition has not been successful in glioblastoma, with the exception of single cases of

encouraging responses in patients with tumors with high mutational burden due to germ line mutations affecting DNA repair [74]. In contrast, large randomized clinical trials of nivolumab versus bevacizumab in recurrent glioblastoma (CheckMate 143) [75] or of nivolumab versus temozolomide, both in combination with radiotherapy, in MGMT promoter unmethylated newly diagnosed glioblastoma (CheckMate 498) have failed to improve survival.

Outlook

The failure of several targeted agents for glioblastoma in late clinical development illustrates that most glioblastomas are not even close to being a single pathway-driven disease that would be amenable to targeted therapy. There is a need for improved clinical trial design and an early inclusion of control arms in phase II settings that allow to arrive at meaningful go/no-go decisions for further clinical development (Table 3). Furthermore, platform trials exploring multiple compounds in parallel would in theory accelerate drug development. EORTC has developed the SPECTA (Screening Cancer Patients for Efficient Clinical Trial Access) platform [76], but this approach has not yet been applied to glioblastoma. Innovative clinical trial concepts such as AGILE (Adaptive Global Innovative Learning Environment for Glioblastoma) and INSIGhT (Individualized Screening Trial of Innovative Glioblastoma Therapy) propose multiple arms that can be enlarged or terminated early in a dynamic manner according to their probability of success which requires continuous monitoring [77]. Such trials may speed drug development significantly, but their success will ultimately depend on whether active compounds are tested in well selected patients. Another, not mutually exclusive approach would assign patients to clinical trial arms based upon molecular profiling in real time. While such clinical trial concepts are overall innovative and promising, there are certain caveats [55]. Molecular testing needs to be done quickly enough to allow patient treatment in adequate time, algorithms to rank the molecular lesions found need to be in place, and pharmaceutical companies need to be motivated to collaborate in early phases of drug development. The only randomized effort to demonstrate a superiority of treatment allocation based on molecular testing over standard of care, the French SHIVA trial, comes from the non-neuro-oncology area and failed to demonstrate overall benefit [78], but profiling techniques have made great progress and novel targets continue to be identified.

Declaration of Competing Interest

ELR has received research grants from Mundipharma and Amgen and honoraria for lectures or advisory board participation from Abbvie, Daiichi Sankyo, Mundipharma and Novartis.

MP has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC

References

[1] Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, et al. Glioma. Nat Rev Dis Primers 2015;1:15017. https://doi.org/10.1038/nrdp.2015.17.

[2] Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–20. https://doi.org/10.1007/s00401-016-1545-1.

[3] Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Acta Neuropathol 2018;136:805–10. https://doi.org/10.1007/s00401-018-1913-0.

[4] Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 2013;37:685–98. https://doi.org/10.1097/PAS.0b013e31827f9c5e.

[5] Korshunov A, Chavez L, Sharma T, Ryzhova M, Schrimpf D, Stichel D, et al. Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. Brain Pathol 2018;28:656–62. https://doi.org/10.1111/bpa.12566.

[6] Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 2017;18:e315–29. https://doi.org/10.1016/S1470-2045(17)30194-8.

[7] Sturm D, Witt H, Hovestadt V, Khuong-Quang D-A, Jones DTW, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012;22:425–37. https://doi.org/10.1016/j.ccr.2012.08.024.

[8] Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155:462–77. https://doi.org/10.1016/j.cell.2013.09.034.

[9] Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation-based classification of central nervous system tumours. Nature 2018;555:469–74. https://doi.org/10.1038/nature26000.

[10] Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96. https://doi.org/10.1056/NEJMoa043330.

[11] Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA 2017;318:2306–16. https://doi.org/10.1001/jama.2017.18718.

[12] Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, et al. Lomustine and

[13] Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 2012;48:2192–202. https://doi.org/10.1016/j.ejca.2012.04.011.

[14] Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003. https://doi.org/10.1056/NEJMoa043331.

[15] Hegi ME, Genbrugge E, Gorlia T, Stupp R, Gilbert MR, Chinot OL, et al. MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: A pooled analysis of four clinical trials. Clin Cancer Res 2019;25:1809–16. https://doi.org/10.1158/1078-0432.CCR-18-3181.

[16] Brandes AA, Finocchiaro G, Zagonel V, Reni M, Caserta C, Fabi A, et al. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. Neuro-Oncology 2016;18:1304–12. https://doi.org/10.1093/neuonc/now035.

[17] Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rudà R, Faedi M, et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 2019;20:110–9. https://doi.org/10.1016/S1470-2045(18)30675-2.

[18] Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: The DIRECTOR trial. Clin Cancer Res 2015;21:2057–64. https://doi.org/10.1158/1078-0432.CCR-14-2737.

[19] Taal W, Oosterkamp HM, Walenkamp AME, Dubbink HJ, Beerepoot LV, Hanse MCJ, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014;15:943–53. https://doi.org/10.1016/S1470-2045(14)70314-6.

[20] Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011;77:1156–64. https://doi.org/10.1212/WNL.0b013e31822f02e1.

[21] Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, et al. Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. J Clin Oncol 2016;34:731–9. https://doi.org/10.1200/JCO.2015.63.6563.

[22] Krauze AV, Myrehaug SD, Chang MG, Holdford DJ, Smith S, Shih J, et al. A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma. Int J Radiat Oncol Biol Phys 2015;92:986–92. https://doi.org/10.1016/j.ijrobp.2015.04.038.

[23] Bobustuc GC, Baker CH, Limaye A, Jenkins WD, Pearl G, Avgeropoulos NG, et al. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro-Oncology 2010;12:917–27. https://doi.org/10.1093/neuonc/noq044.

[24] Grossman SA, Ye X, Chamberlain M, Mikkelsen T, Batchelor T, Desideri S, et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol 2009;27:4155–61. https://doi.org/10.1200/JCO.2008.21.6895.

[25] Seliger C, Genbrugge E, Gorlia T, Chinot O, Stupp R, Nabors B, et al. Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis. Int J Cancer 2019. https://doi.org/10.1002/ijc.32337.

[26] Lassman AB, Rossi MR, Raizer JJ, Razier JR, Abrey LE, Lieberman FS, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01–03 and 00–01. Clin Cancer Res 2005;11:7841–50. https://doi.org/10.1158/1078-0432.CCR-05-0421.

[27] Hegi ME, Diserens A-C, Bady P, Kamoshima Y, Kouwenhoven MCM, Delorenzi M, et al. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib–a phase II trial. Mol Cancer Ther 2011;10:1102–12. https://doi.org/10.1158/1535-7163.MCT-11-0048.

[28] Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 2017;18:1373–85. https://doi.org/10.1016/S1470-2045(17)30517-X.

[29] Van Den Bent MJ, French P, Eoli M, Sepúlveda JM, Walenkamp AME, Frenel J-S, et al. Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406). JCO 2018;36. https://doi.org/10.1200/JCO.2018.36.15_suppl.2023. 2023–2023.

[30] O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 2017;9. https://doi.org/10.1126/scitranslmed.aaa0984.

[31] Gedeon PC, Schaller TH, Chitneni SK, Choi BD, Kuan C-T, Suryadevara CM, et al. A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma. Clin Cancer Res 2018;24:3611–31. https://doi.org/10.1158/1078-0432.CCR-17-0126.

[32] van den Bent MJ, Gao Y, Kerkhof M, Kros JM, Gorlia T, van Zwieten K, et al. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro-Oncology 2015;17:935–41. https://doi.org/10.1093/neuonc/nov013.

[33] Felsberg J, Hentschel B, Kaulich K, Gramatzki D, Zacher A, Malzkorn B, et al.

Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: prognostic role and comparison between primary and recurrent tumors. Clin Cancer Res 2017;23:6846–55. https://doi.org/10.1158/1078-0432.CCR-17-0890.

[34] Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005;23:357–61. https://doi.org/10.1007/s10637-005-1444-0.

[35] Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, et al. Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation: an open-label, multicenter, multi-arm, phase II trial. J Clin Oncol 2019;37:741–50. https://doi.org/10.1200/JCO.18.01207.

[36] Ma DJ, Galanis E, Anderson SK, Schiff D, Kaufmann TJ, Peller PJ, et al. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro-Oncology 2015;17:1261–9. https://doi.org/10.1093/neuonc/nou328.

[37] Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJB, et al. Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). Clin Cancer Res 2016;22:4797–806. https://doi.org/10.1158/1078-0432.CCR-15-3153.

[38] Li Y, Li A, Glas M, Lal B, Ying M, Sang Y, et al. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci USA 2011;108:9951–6. https://doi.org/10.1073/pnas.1016912108.

[39] Chi AS, Batchelor TT, Kwak EL, Clark JW, Wang DL, Wilner KD, et al. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J Clin Oncol 2012;30:e30–3. https://doi.org/10.1200/JCO.2011.38.4586.

[40] Le Rhun E, Chamberlain MC, Zairi F, Delmaire C, Idbaih A, Renaud F, et al. Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients. CNS Oncol 2015;4:381–6. https://doi.org/10.2217/cns.15.30.

[41] Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro-Oncology 2011;13:437–46. https://doi.org/10.1093/neuonc/noq198.

[42] Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, et al. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses. J Clin Oncol 2017;35:343–51. https://doi.org/10.1200/JCO.2015.64.7685.

[43] Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, et al. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro-Oncology 2018;20:259–67. https://doi.org/10.1093/neuonc/nox151.

[44] Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, et al. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro-Oncology 2018;20:249–58. https://doi.org/10.1093/neuonc/nox154.

[45] International Cancer Genome Consortium PedBrain Tumor Project. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat Med 2016;22:1314–20. https://doi.org/10.1038/nm.4204.

[46] Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012;337:1231–5. https://doi.org/10.1126/science.1220834.

[47] Di Stefano AL, Fucci A, Frattini V, Labussiere M, Mokhtari K, Zoppoli P, et al. Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma. Clin Cancer Res 2015;21:3307–17. https://doi.org/10.1158/1078-0432.CCR-14-2199.

[48] Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 2019;381:626–36. https://doi.org/10.1056/NEJMoa1904059.

[49] Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, et al. BRAF inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET study. J Clin Oncol 2018;JCO2018789990. https://doi.org/10.1200/JCO.2018.78.9990.

[50] Wen P, De Greve J, Mason W, Hofheinz R-D, Dietrich S, de Vos F, et al. Neuro Oncol 2018;20:vi238–9. https://doi.org/10.1093/neuonc/noy148.988.

[51] Wen P, Alexander S, Yung-Jue B, van den Bent M, Gazzah A, Dietrich S, et al. Neuro Oncol 2018;20. https://doi.org/10.1093/neuonc/noy148.986. vi238–vi238.

[52] Ferguson SD, Zhou S, Huse JT, de Groot JF, Xiu J, Subramaniam DS, et al. Targetable Gene Fusions Associate with the IDH Wild-Type Astrocytic Lineage in Adult Gliomas. J Neuropathol Exp Neurol 2018;77:437–42. https://doi.org/10.1093/jnen/nly022.

[53] France AED Steven G DuBois, Anna F Farago, Birgit Geoerger, Juneko E Grilley-Olson, David S Hong, Davendra Sohal, Cornelis Martinus van Tilburg, David Simon Ziegler, Nora Ku, Michael Craig Cox, Shivani Nanda, Barrett H Childs, Francois P Doz; Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Cancer Center, Massachusetts General Hospital, Boston, MA; Institut Gustave Roussy, Villejuif, France; University of North Carolina Hospitals, Chapel Hill, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany; Kids Cancer Centre, Sydney Children's Hospital, Randwick, Australia; Loxo Oncology, Inc , South San Francisco, CA; Bayer HealthCare Pharmaceuticals, Inc, Whippany, NJ; Institut Curie, Paris. Welcome. Meeting

[54] Taylor JW, Parikh M, Phillips JJ, James CD, Molinaro AM, Butowski NA, et al. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. J Neurooncol 2018;140:477–83. https://doi.org/10.1007/s11060-018-2977-3.

[55] Wick W, Dettmer S, Berberich A, Kessler T, Karapanagiotou-Schenkel I, Wick A, et al. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro-Oncology 2019;21:95–105. https://doi.org/10.1093/neuonc/noy161.

[56] Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013;110:6021–6. https://doi.org/10.1073/pnas.1303607110.

[57] Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013;339:959–61. https://doi.org/10.1126/science.1230062.

[58] Takahashi M, Miki S, Fujimoto K, Fukuoka K, Matsushita Y, Maida Y, et al. Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer Sci 2019;110:2247–57. https://doi.org/10.1111/cas.14067.

[59] Kong X-T, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E, et al. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. Int J Radiat Oncol Biol Phys 2018;100:1195–203. https://doi.org/10.1016/j.ijrobp.2018.01.001.

[60] Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro-Oncology 2012;14:215–21. https://doi.org/10.1093/neuonc/nor198.

[61] Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740–5. https://doi.org/10.1200/JCO.2008.16.3055.

[62] Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733–40. https://doi.org/10.1200/JCO.2008.19.8721.

[63] Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol 2015;33:2735–44. https://doi.org/10.1200/JCO.2015.61.5005.

[64] Wirsching H-G, Tabatabai G, Roelcke U, Hottinger AF, Jörger F, Schmid A, et al. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. Ann Oncol 2018;29:1423–30. https://doi.org/10.1093/annonc/mdy120.

[65] Szabo E, Schneider H, Seystahl K, Rushing EJ, Herting F, Weidner KM, et al. Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo. Neuro-Oncology 2016;18:1242–52. https://doi.org/10.1093/neuonc/now043.

[66] Gilbert MR, Sulman EP, Mehta MP. Bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370:2048–9. https://doi.org/10.1056/NEJMc1403303.

[67] Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370:709–22. https://doi.org/10.1056/NEJMoa1308345.

[68] Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013;31:3212–8. https://doi.org/10.1200/JCO.2012.47.2464.

[69] Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Maurer G, et al. Integrin control of the transforming growth factor-β pathway in glioblastoma. Brain 2013;136:564–76. https://doi.org/10.1093/brain/aws351.

[70] Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PMJ, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28:2712–8. https://doi.org/10.1200/JCO.2009.26.6650.

[71] Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong Y-K, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071–22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1100–8. https://doi.org/10.1016/S1470-2045(14)70379-1.

[72] Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro-Oncology 2011;13:132–42. https://doi.org/10.1093/neuonc/noq142.

[73] Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, et al. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro-Oncology 2016;18:1146–56. https://doi.org/10.1093/neuonc/now009.

[74] Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 2016;34:2206–11. https://doi.org/10.1200/JCO.2016.66.6552.

[75] Reardon DA, Omuro A, Brandes AA, Rieger J, Wick A, Sepulveda J, et al. OS10.3 randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro Oncol 2017;19:iii21. https://doi.org/10.1093/neuonc/nox036.071.

[76] Lacombe D, Tejpar S, Salgado R, Cardoso F, Golfinopoulos V, Aust D, et al. European perspective for effective cancer drug development. Nat Rev Clin Oncol 2014;11:492–8. https://doi.org/10.1038/nrclinonc.2014.98.

[77] Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, et al. Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clin Cancer Res 2018;24:737–43. https://doi.org/10.1158/1078-0432.CCR-17-0764.

[78] Le Tourneau C, Delord J-P, Gonçalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015;16:1324–34. https://doi.org/10.1016/S1470-2045(15)00188-6.

[79] Kwak Y, Kim S-I, Park C-K, Paek SH, Lee S-T, Park S-H. C-MET overexpression and amplification in gliomas. Int J Clin Exp Pathol 2015;8:14932–8.

[80] Plate KH, Breier G, Weich HA, Mennel HD, Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994;59:520–9. https://doi.org/10.1002/ijc.2910590415.

[81] Frei K, Gramatzki D, Tritschler I, Schroeder JJ, Espinoza L, Rushing EJ, et al. Transforming growth factor-β pathway activity in glioblastoma. Oncotarget 2015;6:5963–77. https://doi.org/10.18632/oncotarget.3467.

[82] Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wöhrer A, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology 2015;17:1064–75. https://doi.org/10.1093/neuonc/nou307.

[83] Nduom EK, Wei J, Yaghi NK, Huang N, Kong L-Y, Gabrusiewicz K, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology 2016;18:195–205. https://doi.org/10.1093/neuonc/nov172.

[84] van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MCM, Kros JM, Carpentier AF, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009;27:1268–74. https://doi.org/10.1200/JCO.2008.17.5984.

[85] Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, et al. A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients. Clin Cancer Res 2015;21:3610–8. https://doi.org/10.1158/1078-0432.CCR-14-3220.

[86] Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, et al. Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: The randomized GLARIUS trial. J Clin Oncol 2016;34:1611–9. https://doi.org/10.1200/JCO.2015. 63.4691.

[87] de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 2011;29:2689–95. https://doi.org/10.1200/JCO.2010.34.1636.

[88] Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010;28:2817–23. https://doi.org/10.1200/JCO.2009.26.3988.

[89] Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26:5610–7. https://doi.org/10.1200/JCO.2008.16.7510.

[90] Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G, et al. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 2012;118:5601–7. https://doi.org/10.1002/cncr.27585.

[91] Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, et al. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro-Oncology 2015;17:708–17. https://doi.org/10.1093/neuonc/nou356.

[92] Reardon DA, Lassman AB, Schiff D, Yunus SA, Gerstner ER, Cloughesy TF, et al. Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer 2018;124:1438–48. https://doi.org/10.1002/cncr.31172.

[93] Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010;28:1168–74. https://doi.org/10.1200/JCO.2009.23.2595.

[94] Wick W, Steinbach JP, Platten M, Hartmann C, Wenz F, von Deimling A, et al. Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neuro-Oncology 2013;15:1405–12. https://doi.org/10.1093/neuonc/not100.

[95] Iwamoto FM, Kreisl TN, Kim L, Duic JP, Butman JA, Albert PS, et al. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer 2010;116:1776–82. https://doi.org/10.1002/cncr.24957.

[96] Wick W, Fricke H, Junge K, Kobyakov G, Martens T, Heese O, et al. A phase II, randomized, study of weekly APG101 + reirradiation versus reirradiation in progressive glioblastoma. Clin Cancer Res 2014;20:6304–13. https://doi.org/10.1158/1078-0432.CCR-14-0951-T.